Comparing two imaging scans for prostate cancer screening in men
Compares a new ultrasound scan with MRI to see which better images the prostate.
Plain-language title generated from the registry record
Registry title: Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Key facts
- Where
- Edmonton, Montreal, Toronto, and Vancouver, CanadaSee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT06626022, who can take part
Where in Canada
- University of AlbertaEdmonton, CanadaNo longer taking part
- CIUSSS du Nord-de-L'Ile-De-MontrealMontreal, CanadaNot yet recruiting
- Sunnybrook Health Sciences CentreToronto, CanadaTaking people
- University of British ColumbiaVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alberta
- Trial code
- NCT06626022
- Record updated
- 25 September 2026
- Original description
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.Read full original descriptionShow less
A Phase 3, Multicenter, International, Non-inferiority, Randomized Clinical Trial Comparing Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging (MUSIC-Screen)
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.
Inclusion: Male sex; Age 50-70; PSA 3-20 and/or abnormal DRE; Biopsy naïve.
Exclusion: Prior personal history of prostate cancer; Prior prostate imaging using microUS or MRI; Testosterone replacement therapy within last 12 months; or; Androgen deprivation therapy within last 12 months; Contraindication to microUS or MRI.